Quantcast
Last updated on April 17, 2014 at 13:27 EDT

Latest ketoprofen Stories

2014-04-12 23:02:07

Topical pain relief creams such as Lidocream, Ketocream, Indocream, and Gabacream are introduced and described. Los Angeles, CA (PRWEB) April 12, 2014 Well-known compounding pharmacist and entrepreneur in Beverly Hills, Dr. Hootan Melamed, has introduced a range of proven and effective formulated creams that are designed to provide relief from inflammation and pain. In many cases, mass produced medications may not be able to provide adequate relief or may cause side effects in certain...

2013-04-18 08:30:50

Imprimis Pharmaceuticals, Inc., Concluded its April 15th, 2013 Meeting with the FDA in Washington, D.C., and Reviewed the Company's Development Program for its Lead Phase III Drug Candidate, Impracor(TM) SOLANA BEACH, Calif., April 18, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) today announced that on April 15(th), 2013, the Company attended its Type C meeting with the U.S. Food and Drug Administration (FDA) which included the review of the development plan for...

2013-02-19 08:32:52

SOLANA BEACH, Calif., Feb. 19, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY:NASDAQ) today announced the completion of a clinical study of Impracor(TM), a topical analgesic cream that delivers a therapeutic dose of the pain-relieving, anti-inflammatory drug ketoprofen. The study measured the amount of ketoprofen found in the bloodstream following topical application of two different doses of the anti-inflammatory cream under different conditions, including normal activities, heat...

2012-12-18 16:24:47

SOLANA BEACH, Calif., Dec. 18, 2012 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY: OTCQB) today announced that Gus Bassani, Pharm. D., Vice President of Consulting, R&D and Formulations with the Professional Compounding Centers of America, Inc. (PCCA), will join its board of directors. Imprimis Pharmaceuticals is dedicated to improving patient health and quality of life by leveraging a patented topical drug delivery platform that enables highly targeted site specific...

2012-09-19 02:30:05

SOLANA BEACH, Calif., Sept. 19, 2012 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY:OTCQB) today announced the initiation of a clinical study of Impracor(TM), a topical cream that delivers a dose of the pain-relieving, anti-inflammatory drug ketoprofen. The study will measure the amount of ketoprofen found in the bloodstream following topical application of two different doses of the anti-inflammatory cream under different "real world' conditions, including normal...

2012-08-20 02:30:24

SOLANA BEACH, Calif., Aug. 20, 2012 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (OTC Markets Group: IMMY), a specialty pharmaceutical company developing non-invasive, topically delivered products, announced that it has signed an agreement with DPT Labs (www.dptlabs.com) to commence work on supplying Imprimis with quantities of its active topical anti-inflammatory drug, Impracor, for currently planned Phase 3 clinical trials. Impracor is the first drug to be developed using Imprimis's...

2012-04-27 02:26:18

SOLANA BEACH, Calif., April 27, 2012 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (OTC Markets: IMMY) announced that it has closed a $7.95M private placement of stock and warrants and is providing an update to shareholders and the market. Imprimis Pharmaceuticals, Inc. CEO Mark L. Baum stated, "We are pleased to announce the closing of a $7.95M private placement. The financing was completed at a price of $0.79 per unit and included one share of common stock and a 25% three year warrant,...

2011-06-27 08:00:00

SAN DIEGO, June 27, 2011 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that it had entered into an agreement with Transdel Pharmaceuticals to acquire substantially all of Transdel's business assets including a Phase 3 product candidate Ketotransdel(TM) (TDLP-110), which is a topically-administered analgesic for the treatment of musculoskeletal pain. The business assets would be acquired in connection with a proposed asset purchase under Section 363 of Chapter 11 of...

2011-02-01 07:00:00

LA JOLLA, Calif., Feb. 1, 2011 /PRNewswire/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, today announced that the Company has been exploring strategic alternatives aimed at enhancing shareholder value with two investment banks, American MedTech Advisors and ESC Advisors, a division of KEMA Partners. The goal of this engagement is to...

2010-09-02 07:00:00

MONTREAL, Sept. 2 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, announced today the final data set from its Phase 3 study of Ketotransdel® (TDLP-110) at the 13th World Congress on Pain in Montreal, Canada. TDLP-110, the Company's lead pain product candidate, utilizes its transdermal delivery...